Janssen Pharmaceutica NV Completes Divestiture Of Animal Health Business To Elanco, A Division Of Eli Lilly And Company
Janssen Pharmaceutica NV Completes Divestiture Of Animal Health Business To Elanco, A Division Of Eli Lilly And Company
Beerse, Belgium (July 7, 2010) – Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies, today announced it has completed the divestiture of its Animal Health business to Elanco, a Division of Eli Lilly and Company. Financial terms of the transaction are not being disclosed.
Under the terms of the transaction, Elanco acquires products, contracts and related intellectual property and marketing authorizations. The terms of the offer also include that the employees, active in 11 different countries, transfer to Elanco to support a significantly expanded portfolio of products.
About Janssen Pharmaceutica
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases & vaccines, and cardiovascular & metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Pharmaceutica N.V. is one of the Janssen Pharmaceutical Companies.
About Janssen Animal Health
Janssen Animal Health is a division within Janssen Pharmaceutica, Beerse (Belgium) with operations in 11 countries. It focuses on targeted disease segments in companion animals and livestock with special focus on pigs and poultry.
###
Media
Stefan Gijssels
Janssen Pharmaceutica NV
+32 473 710 425
Investor Relations
Stan Panasewicz
Johnson & Johnson
1-732-524-2524
Louise Mehrotra
Johnson & Johnson
1-732-524-6491